BR112017013300A2 - alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições. - Google Patents

alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.

Info

Publication number
BR112017013300A2
BR112017013300A2 BR112017013300A BR112017013300A BR112017013300A2 BR 112017013300 A2 BR112017013300 A2 BR 112017013300A2 BR 112017013300 A BR112017013300 A BR 112017013300A BR 112017013300 A BR112017013300 A BR 112017013300A BR 112017013300 A2 BR112017013300 A2 BR 112017013300A2
Authority
BR
Brazil
Prior art keywords
alpha galactosidase
recombinant
composition
compositions
fabry
Prior art date
Application number
BR112017013300A
Other languages
English (en)
Inventor
W Huisman Gjalt
G Miller Mathew
J Agard Nicholas
Zhang Xiyun
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of BR112017013300A2 publication Critical patent/BR112017013300A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção provê polipeptídeos de alfa-galactosidase humana engenheirados e composições dos mesmos. os polipeptídeos de alfa-galactosidase humana engenheirados foram aprimorados para prover estabilidade melhorada em condições tanto ácidas (ph <4,5) quanto básicas (ph >7). a invenção também se refere ao uso das composições compreendendo os polipeptídeos de alfa-galactosidase humana engenheirados para propósitos terapêuticos.
BR112017013300A 2014-12-22 2015-12-02 alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições. BR112017013300A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095313P 2014-12-22 2014-12-22
US201562216452P 2015-09-10 2015-09-10
PCT/US2015/063329 WO2016105889A1 (en) 2014-12-22 2015-12-02 Human alpha-galactosidase variants

Publications (1)

Publication Number Publication Date
BR112017013300A2 true BR112017013300A2 (pt) 2018-02-27

Family

ID=56151383

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013300A BR112017013300A2 (pt) 2014-12-22 2015-12-02 alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.

Country Status (19)

Country Link
US (5) US20170360900A1 (pt)
EP (2) EP4234699A1 (pt)
JP (4) JP6650943B2 (pt)
KR (2) KR102438885B1 (pt)
AU (2) AU2015370125B2 (pt)
BR (1) BR112017013300A2 (pt)
CA (1) CA2970638A1 (pt)
DK (1) DK3237621T3 (pt)
ES (1) ES2944889T3 (pt)
FI (1) FI3237621T3 (pt)
HR (1) HRP20230468T1 (pt)
HU (1) HUE062016T2 (pt)
IL (1) IL252479B (pt)
LT (1) LT3237621T (pt)
PL (1) PL3237621T3 (pt)
PT (1) PT3237621T (pt)
RS (1) RS64574B1 (pt)
SI (1) SI3237621T1 (pt)
WO (1) WO2016105889A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438885B1 (ko) 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11040114B2 (en) 2015-12-24 2021-06-22 Oxyrane Uk Limited Human alpha-N-acetylgalactosaminidase polypeptide
WO2020047282A1 (en) 2018-08-29 2020-03-05 University Of Copenhagen Lysosomal enzymes modified by cell based glycoengineering
KR20210106537A (ko) * 2018-12-20 2021-08-30 코덱시스, 인코포레이티드 인간 알파 갈락토시다제 변이체
WO2021055801A1 (en) * 2019-09-18 2021-03-25 The Medical College Of Wisconsin, Inc. Improved alpha-galactosidase protein for enzyme replacement therapy (ert) and methods of use
US11970722B2 (en) 2019-12-20 2024-04-30 Codexis, Inc. Engineered acid alpha-glucosidase variants
CN116096898A (zh) * 2020-02-28 2023-05-09 科德克希思公司 人类α半乳糖苷酶变体

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US753653A (en) 1903-09-14 1904-03-01 American Car & Foundry Co Hopper-bottom car.
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
AU2705895A (en) 1994-06-30 1996-01-25 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
EP1538202B1 (en) 1996-09-13 2014-01-22 Shire Human Genetic Therapies, Inc. Production of human alpha-galactosidase A
EP1717322B1 (en) 1997-01-17 2012-07-18 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6537746B2 (en) 1997-12-08 2003-03-25 Maxygen, Inc. Method for creating polynucleotide and polypeptide sequences
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
ATE465459T1 (de) 1999-01-19 2010-05-15 Maxygen Inc Durch oligonukleotide-vermittelte nukleinsäuren- rekombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
WO2001075767A2 (en) 2000-03-30 2001-10-11 Maxygen, Inc. In silico cross-over site selection
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US7783428B2 (en) 2002-03-01 2010-08-24 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
AU2003213846A1 (en) 2002-03-09 2003-09-29 Maxygen, Inc. Optimization of crossover points for directed evolution
EP1503788B1 (en) * 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8768871B2 (en) 2008-02-12 2014-07-01 Codexis, Inc. Method of generating an optimized, diverse population of variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
ES2575005T3 (es) 2008-06-13 2016-06-23 Codexis, Inc. Método de síntesis de variantes de polinucleótidos
US9194011B2 (en) * 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US8876066B1 (en) 2009-12-17 2014-11-04 Progressive Fastening, Inc. Hanger with bolt closures
WO2011097335A2 (en) 2010-02-04 2011-08-11 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
CN102933707B (zh) * 2010-03-02 2015-09-30 普罗塔里克斯有限公司 稳定的α-半乳糖苷酶及其用途
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
EP2726651B1 (en) 2011-06-28 2018-11-07 Codexis, Inc. Protein variant generation by region shuffling
EP2825647A4 (en) 2012-03-15 2015-10-14 Codexis Inc METHODS OF GENE REARRANGING
WO2013156552A1 (en) 2012-04-18 2013-10-24 Vib Vzw Means and methods for generating improved proteins
EP2951579B1 (en) 2013-01-31 2024-04-24 Codexis, Inc. Methods, systems, and software for identifying bio-molecules using models of multiplicative form
AU2014324669B2 (en) 2013-09-27 2020-06-04 Codexis, Inc. Automated screening of enzyme variants
NZ717647A (en) 2013-09-27 2020-06-26 Codexis Inc Structure based predictive modeling
KR102438885B1 (ko) 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
KR20210106537A (ko) * 2018-12-20 2021-08-30 코덱시스, 인코포레이티드 인간 알파 갈락토시다제 변이체

Also Published As

Publication number Publication date
KR102438885B1 (ko) 2022-09-01
EP4234699A1 (en) 2023-08-30
KR20170093976A (ko) 2017-08-16
US20170360900A1 (en) 2017-12-21
CA2970638A1 (en) 2016-06-30
US20200360489A1 (en) 2020-11-19
JP2018500907A (ja) 2018-01-18
EP3237621B1 (en) 2023-04-19
WO2016105889A1 (en) 2016-06-30
NZ732171A (en) 2021-01-29
AU2022202939A1 (en) 2022-05-26
JP2022097653A (ja) 2022-06-30
FI3237621T3 (fi) 2023-06-01
AU2015370125B2 (en) 2022-02-03
JP6650943B2 (ja) 2020-02-19
US20210244804A1 (en) 2021-08-12
EP3237621A4 (en) 2018-12-05
US20200405826A1 (en) 2020-12-31
EP3237621A1 (en) 2017-11-01
LT3237621T (lt) 2023-09-25
JP2019076110A (ja) 2019-05-23
US20200360490A1 (en) 2020-11-19
KR20220123342A (ko) 2022-09-06
US10973888B2 (en) 2021-04-13
PL3237621T3 (pl) 2023-10-30
SI3237621T1 (sl) 2023-11-30
IL252479A0 (en) 2017-07-31
US11278600B2 (en) 2022-03-22
HUE062016T2 (hu) 2023-09-28
JP2021003129A (ja) 2021-01-14
RS64574B1 (sr) 2023-10-31
PT3237621T (pt) 2023-07-20
HRP20230468T1 (hr) 2023-11-10
US11497798B2 (en) 2022-11-15
ES2944889T3 (es) 2023-06-26
DK3237621T3 (da) 2023-06-19
AU2015370125A1 (en) 2017-06-22
IL252479B (en) 2021-03-25

Similar Documents

Publication Publication Date Title
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201591839A1 (ru) Терапевтические пептиды
BR112017023269A2 (pt) métodos para tratamento de câncer
EA201700507A1 (ru) Композиция, клетки, способы получения полипептида, применение полипептида и клеток, способ лечения
BR112016017041A2 (pt) Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição
MX2016016337A (es) Polipeptidos apelina.
BR112016024379A2 (pt) variantes ldlr e seu uso em composições para reduzir os níveis de colesterol
MY187047A (en) Selective pyy compounds and uses thereof
EA201492053A1 (ru) Белки фактора роста фибробластов 21
EA201990071A1 (ru) Композиция пептидной вакцины
BR112019023337A2 (pt) Ligase engenheirada, sequência de polinucleotídeo, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo da ligase engenheirada, um produto de ligação, uma biblioteca de dna e uma pluralidade de fragmentos de dna adequados para sequenciamento, e, composição
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
EP4324845A3 (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
BR112016027024A2 (pt) polipeptídeos de ligação específica e seus usos
AU2014375637A1 (en) Formula of neuregulin preparation
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
BR112015022181A2 (pt) proteínas da substância de inibição mulleriana modificada (mis) e usos das mesmas para o tratamento da(s) doenças
BR112016030730A8 (pt) composto
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
BR112017028225A2 (pt) ?composição?
BR112017002741A2 (pt) peptídeos contendo manose-6-fosfato fundidos a enzimas lisossômicas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]